Strengthening African Health Systems through Impact Investing



Steven Adjei, BPharm(Hons), MRPharmS, MBA is the founding partner of BlueCloud™ Healthcare. Steven is a writer, entrepreneur, speaker, blogger and a pharmaceutical professional with over 12 years experience in pharmaceutical, community and regulatory healthcare spanning Africa and the UK. He has worked as a pharmaceutical consultant for most of the premier retail chains in the UK including Boots, Sainsbury’s and The Co-operative Group. Steven is a regular participant in African investment forums in Europe and has a passion for facilitation of FDI into African healthcare businesses. Steven holds a Bachelor in Pharmacy from KNUST in Ghana,. He is also a registered clinical pharmacist in Ghana and the UK and is a keen running enthusiast, having completed a number of half marathons and charity races to raise funds for various projects in Africa and the UK.
Les FuntleyderLes Funtleyder is a portfolio manager at E Squared Capital Management, where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. Previously, Mr. Funtleyder was the Director of Strategic Investments for Opko Health, Phil Frost’s holding company. Prior to this, he was a healthcare strategist and portfolio manager for the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX). He joined Miller Tabak, after managing a healthcare portfolio for Provident Advisors, a hedge fund in Minneapolis. Previously, Les worked as a medical device analyst at UBS Warburg. He also covered Biotechnology stocks at Bigelow and company. His industry experience includes directing clinical and business research at Innovative Health Solution, a joint venture of Merck and Wyeth; and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. He started his healthcare career at Empire Blue Cross/Blue Shield. Mr. Funtleyder is the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services, which bridges the gap between health reform, innovation and investing. He is widely quoted in the Wall Street Journal, The New York Times, and The Financial Times, and he is a frequent guest on CNBC, Bloomberg and NPR. He is also a consulting partner to Bluecloud Health, a Sub-Saharan healthcare private equity fund, and on the board of several healthcare companies and foundations. Mr. Funtleyder is currently an Adjunct Professor of Public Health at Columbia University. He earned his Masters of Public Health from Columbia University Mailman School of Public Health, and studied English and Economics at Tulane University.
Alex Hakuzimana, MD, MPH, MBA is a partner of BlueCloud Healthcare. He is an MBA-educated public health specialist and public policy consultant. He is also an adjunct professor and a researcher. He has over 12 years of extensive experience in strategic forward planning, health policy development, project management and capacity development in public and private health programmes in Sub Saharan Africa and Caribbean. Dr. Alex has worked and consulted with several public the German Agency for International Development (GIZ), the UN and Clinton Foundation. Dr. Alex holds a medical degree from University of Rwanda, an MPH from the Institute of Tropical Medicine in Antwerp in Belgium and an MBA from Swiss Management Center University in Switzerland.
Amish Kanabar, MBChB, DCH, MRCGP, PGDip Urology, PGCert MedEdu is a founding partner of of BlueCloud™ Healthcare. He is also an Entrepreneur, Hospital Board Executive, General Practitioner (GP) with a special interest in Urology, and a certified UK GP Trainer and Appraiser. He also has past experience in Pharmaceutical Industry within Regional Medical Affairs at GSK UK Pharma. Amish is a regular speaker and panelist at Africa Healthcare Summits in UK + East Africa and is liaising with PE firms & Financiers to secure bankable healthcare projects in Sub Saharan Africa. Amish graduated from Leicester Medical School and completed his GP training at Oxford. His main passion is introducing and adapting primary and secondary healthcare models into the African healthcare space. Amish has climbed to the summit of Mt Kilimanjaro and is keen squash player.
Sunita Singh-DalalSunita Singh Dalal has been practicing corporate and commercial law for the past 18 years with a strong focus on healthcare, education and hospitality. She was a Partner with the Africa Legal Network for four years during which she focused on her interest in emerging and developing markets. Sunita is active in her pursuit to encourage the growth of cross-border trade by introducing strategic investors to Africa, Southwest Asia and the Middle East. She is currently working on various healthcare projects in Africa and would like to create a self-sustainable ecosystem for the delivery of affordable healthcare for all Africans. Sunita was named a key India lawyer in the India Business Law Journal’s 2017 Global Stars report and in October 2017 was conferred an international accolade of recognition by the Indian Corporate Counsel Association (ICCA) of India’s Most Trusted Corporate Lawyers. Sunita is also the regional leader for LABFA (Legal and Businesswomen for Africa).
Abhinav SrivastavaAbhinav Srivastava, BA, MsC, MBA (Warwick) is a Partner with BlueCloudHealthcare. He is an experienced management consultant with expertise in research, business development and strategic planning. He co-founded and runs The Strategy Boutique, one of India’s fastest growing niche firms advising clients from across the world. He is involved with developing business plans and strategies across various sectors including hospitality, healthcare and manufacturing. Abhinav has also created and managed a high performance, eight-member global research team for an economics intelligence product, helped innovate and expand its scope to align with changing client requirements, and worked on formulating marketing strategies and generating business for a corporate networking start-up. The Strategy Boutique is working in conjunction with BlueCloud in setting up diagnostic centers across Africa. Abhinav presented a paper on Human Capital in Emerging Countries at the American Economics Association’s Annual Convention in San Francisco, and has been a frequent participant in leading global conferences across the world. Abhinav has a BA in Economics from Hindu College, University of Delhi, an MsC in Economics from the University of Leeds, and an MBA from the Warwick Business School.
RobertSmithICVRobert Smith, Partner, has spent most of his career managing capital for some of the largest financial institutions and identifying traditional and alternative investment opportunities for family offices. He serves as Business Strategy Advisor to New Frontier Bio, a multi-asset holding company, which leverages the long-term involvement of the Kennedy family in healthcare to identify, finance and develop novel medical technologies from inception through clinical proof of concept. Robert serves as a member of the President’s Leadership Council of Thomas Jefferson University and Jefferson Health, 16th on U.S. News & World Report’s 2017-2018 Best Hospitals Honor Roll. He serves on the Sustainable Investing Advisory Board of the United Nations Capital Development Fund (UNCDF), which makes public and private finance work for the poor in the world’s 47 Least Developed Countries (LDCs).

Resource Library
  • Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw-Hill Finance & Investing)
  • Here’s how the Johnson and Johnson stock could move after its opioid… (CNBC)
  • Top Picks in Health-Care Sector (CNBC)
  • Funtleyder Calls Trump’s Health Order a ‘Nothing Burger’ (Bloomberg)
  • People are Going to be Sick Whether Obamacare is Repealed or Not (CNBC)
  • We’re Short Biotech and Large Pharma: Pro (CNBC)
  • Healthcare is in a Holding Pattern CNBC)
  • Funtleyder Says Walmart-Humana Deal a ‘Little Odd’ (Bloomberg)
  • China’s Investors Pour Into Western Biotech Startups (The Wall Street Journal)
  • Pfizer, Merck Take Different R&D Tacks (The Wall Street Journal)
  • Dialysis Firm Bets on Branching Out (The Wall Street Journal)
  • Open-Government Laws Fuel Hedge-Fund Profits (The Wall Street Journal)